- Home
- KTTA vs AIMD Comparison
KTTA vs AIMD Comparison
Compare KTTA & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- AIMD
- Stock Information
- Founded
- KTTA 2020
- AIMD 1984
- Country
- KTTA United States
- AIMD United States
- Employees
- KTTA N/A
- AIMD N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- AIMD Health Care
- Exchange
- KTTA Nasdaq
- AIMD Nasdaq
- Market Cap
- KTTA 4.5M
- AIMD 5.2M
- IPO Year
- KTTA 2021
- AIMD N/A
- Fundamental
- Price
- KTTA $3.99
- AIMD $0.55
- Analyst Decision
- KTTA
- AIMD
- Analyst Count
- KTTA 0
- AIMD 0
- Target Price
- KTTA N/A
- AIMD N/A
- AVG Volume (30 Days)
- KTTA 2.9M
- AIMD 769.6K
- Earning Date
- KTTA 11-11-2024
- AIMD 11-07-2024
- Dividend Yield
- KTTA N/A
- AIMD N/A
- EPS Growth
- KTTA N/A
- AIMD N/A
- EPS
- KTTA N/A
- AIMD N/A
- Revenue
- KTTA N/A
- AIMD $65,122.00
- Revenue This Year
- KTTA N/A
- AIMD N/A
- Revenue Next Year
- KTTA N/A
- AIMD N/A
- P/E Ratio
- KTTA N/A
- AIMD N/A
- Revenue Growth
- KTTA N/A
- AIMD N/A
- 52 Week Low
- KTTA $3.61
- AIMD $0.45
- 52 Week High
- KTTA $17.40
- AIMD $4.29
- Technical
- Relative Strength Index (RSI)
- KTTA 41.34
- AIMD 54.23
- Support Level
- KTTA $3.93
- AIMD $0.46
- Resistance Level
- KTTA $5.45
- AIMD $0.52
- Average True Range (ATR)
- KTTA 0.39
- AIMD 0.04
- MACD
- KTTA -0.13
- AIMD 0.01
- Stochastic Oscillator
- KTTA 2.80
- AIMD 67.73
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.